Abstrakt

The cornerstone of pulmonary embolism therapy is anticoagulation. In cases of existing or impending hemodynamic instability, reperfusion strategies become the primary focus. The choice of initial anticoagulation depends on the patient’s risk stratification. Special populations such as pregnant patients, those with advanced kidney disease, or patients with persistent malignancy require tailored management. After the initial treatment phase, it is important to consider during the maintenance phase which patients may require long-term anticoagulation or thrombophilia testing.

Autoreninformation

Autoren

• J.L. Kühnle
• M. Leitner
• T.M. Rixecker

Abteilungen

• Klinik für Innere Medizin V – Pneumologie, Allergologie, Beatmungs- und Umweltmedizin, Universitätsklinikum des Saarlandes, Homburg

Adresse

Dr. Torben M. Rixecker
Universitätsklinikum des Saarlandes
Klinik für Innere Medizin V –
Pneumologie, Allergologie, Beatmungs- und Umweltmedizin
Kirrberger Straße
66421 Homburg
Email: [email protected]

Citation